

**Corp. Office** : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.  
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

97/LG/SE/AUGUST/2020/GBSL

**August 10, 2020**

To  
The Manager (CRD)  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001

To  
The Manager  
**National Stock Exchange Of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code : 509079**

**Symbol : GUFICBIO**


Dear Sirs,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

This is in reference with the Scheme of Amalgamation of Gufic Biosciences Limited ('the Company') with Gufic Lifesciences Private Limited ("GLPL") and their respective shareholders and creditors, for which "No Observation Letters" have been received by BSE Limited and National Stock Exchange of India Limited vide their letters dated April 15, 2020. Further, the Company has made application before Hon'ble National Company Law Tribunal, Mumbai bench ("NCLT") for sanction of the Scheme and vide its order dated July 14, 2020, the Company shall hold the Shareholder Meeting for their approval on the Scheme on September 15, 2020 . Post amalgamation, the Company will enjoy the benefits as stated hereinabove.

As informed in the Management Report submitted on July 31, 2020 along with the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2020, GLPL has entered into a Loan License Agreement with Hetero Labs Limited ("Hetero") to manufacture and supply Remdesivir Lyophilised Powder for injection (100 mg/vial) on loan license basis to Hetero for its sale in various countries including India. Hetero was the first company in India to launch Remdesivir Lyophilised Powder for injection indicated for emergency use in COVID 19 patients.

Kindly be further informed that Remdesivir will be manufactured in the state-of-the-art Lyophilisation facility of GLPL situated at Navsari, Gujarat and the said facility has been approved by EU-GMP, WHO-GMP, Ukraine GMP , South African authority, ANVISA ,Brazil and



**Corp. Office** : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.  
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

many other countries. GLPL has already received manufacturing license for the said formulation from the drug authorities in India and has also initiated supplies in countries like –Kazakhstan, Phillipines, UAE, Indonesia etc

Gufic Representative Mr Y. Nagesh said *“Gufic is glad to contribute towards the global fight against COVID 19 by manufacturing quality medicines at our state-of-the art facility. We are completely committed to fulfil the unmet demand of Remdesivir in the domestic as well as international market through our recently expanded Lyophilisation facility at Navsari.”*

*The Company and GLPL have expanded their infrastructure and it has now a capacity of over 50 million vials per annum which makes Gufic group as one of the World’s largest manufacturer of Lyophilised products”.*

The brief description about the **Remdesivir is specified as below :**

“Remdesivir Lyophilised Powder for Injection is an investigational new drug developed by Gilead Sciences Inc, a Delaware Corporation based in California, USA. The USFDA granted Emergency Use Authorization of Remdesivir to treat hospitalized patients with severe COVID 19 in the Unites States. In addition, it is recommended for compassionate use in Europe and recently received regulatory approval in Japan, Taiwan and Singapore.”

Kindly take the same on record.

Yours faithfully,

**For Gufic Biosciences Limited**



**Ami Shah**

**Company Secretary**

**Membership No. A39579**

